|
|||||
|
|
| 乳腺癌组织蛋白质谱的差异对新辅助化疗疗效中的预测 | |
| 引用本文： | 李庆,张坤,付荣湛,顾禾,张丽丽,袁凯,王玉龙,陈守华. 乳腺癌组织蛋白质谱的差异对新辅助化疗疗效中的预测[J]. 内分泌外科杂志, 2013, 0(1): 42-45 |
| 作者姓名： | 李庆 张坤 付荣湛 顾禾 张丽丽 袁凯 王玉龙 陈守华 |
| 作者单位： | 山东省千佛山医院普外中心两腺外科,250012 |
| 基金项目： | 山东省自然科学基金（y2008c15） |
| 摘 要： | 目的应用表面增强激光解析／电离化时间-飞行质谱技术（SELDI—TOF MS）检测乳腺癌患者新辅助化疗前的癌组织蛋白质谱的差异，筛选有疗效预测价值的相关蛋白。方法用SELDI—TOF MS技术检测30例乳腺癌治疗前的癌组织标本，获得蛋白质谱，行新辅助化疗后，根据RECIST标准评价疗效，分为新辅助化疗有效组（CR＋PR，19例）和无效组（SD＋PD，11例），比较2组蛋白质谱差异。结果2组比较，筛选出11个蛋白峰差异有统计学意义（P〈0．05），分别为：3491Da（t=3．189，P=0．004）、5158Da（t=3．897，P=0．001）、5360Da（t=2．157，P=0．04）、7549Da（t=2．173，P=0．038）、8451Da（t=2．258，P：0．032）、8694Da（t=3．234，P=0．003）、9089Da（t=2．653，P=0．013）、10528Da（t=3．127，P=0．004）、13445Da（t=2．231，P=0．034）、15118Da（t=3．255，P=0．003）、44065Da（t=2．554，P=0．017）。这些蛋白峰强度有效组均较无效组高。结论应用SELDI—TOFMS技术可筛选出乳腺癌化疗敏感相关的组织蛋白质谱。 |
| 关 键 词： | 乳腺肿瘤 新辅助化疗 蛋白质组学 |
Different protein spectrum of breast cancer tissues in predicting curative effects of neoadjuvant chemotherapy |
|
| LI Qing,ZHANG Kun,FU Rong-zhan,GU He,ZHANG Li-li,YUAN Kai,WANG Yu-long,CHEN Shou-hua. Different protein spectrum of breast cancer tissues in predicting curative effects of neoadjuvant chemotherapy[J]. , 2013, 0(1): 42-45 | |
| Authors: | LI Qing ZHANG Kun FU Rong-zhan GU He ZHANG Li-li YUAN Kai WANG Yu-long CHEN Shou-hua |
| Affiliation: | ( Department of General Surgery, Qian Foshan Hospital Affiliated to Shandong University, Jinan 250014, China) |
| Abstract: | Objective To find out related proteins that could possibly predict curative effects of neoadjuvant chemotherapy（NACT） by applying surface-enhanced laser desorption/ionization time-of-flight mass spectrum- etry（ SELDI-TOF MS） to detect the difference in protein spectrum of breast cancer tissues. Methods Cancer tissue samples from 30 cases of breast cancer patients were detected by SELDI-TOF MS before NACT to get protein spectrum of breast cancer tissues. After NACT, the curative effects were evaluated according to RECIST standard and patients were divided into effective group（ 19 cases with complete response or partial response）and invalid group（ 11 cases with stable disease or progressive disease）. Results 11 different protein peaks （ P 〈 0. 05 ） were screened out：3491 Da（t =3. 189 P =0. 004）, 5158 Da（t =3. 897 P =0.001）, 5360 Da（t =2. 157 P =0. 04）, 7549 Da（t=2.173 P=0.038）,8451 Da（t=2.258 P=0.032）, 8694 Da（t=3.234 P=0.003）, 9089 Da （t =2.653 P=0.013）, 10528 Da（t =3. 127 P =0.004）, 13445 Da（t =2.231 P =0.034）, 15118 Da（t= 3. 255 P =0. 003）, and 44065 Da（t =2. 554 P =0. 017）. They were all expressed higher in effective group than in invalid group. The difference had statistical significance（P 〈 0. 05 ）. Conclusion SELDI-TOF MS technology can screen out protein spectrum sensitive to NACT, providing evidences for breast cancer patients whether or not taking NACT. |
| Keywords: | Breast tumor Neoadjuvant chemotherapy Proteomies |
| 本文献已被 维普 等数据库收录！ | |